Complement Inactivating Agents

"Complement Inactivating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host.

Descriptor ID	D051056
MeSH Number(s)	D27.505.696.477.656.500
Concept/Terms	Complement Inactivating Agents Complement Inactivating Agents Agents, Complement Inactivating Inactivating Agents, Complement Complement Inhibitors Inhibitors, Complement Complement Inhibiting Agents Agents, Complement Inhibiting Inhibiting Agents, Complement Complement Cytolysis Inhibiting Agents Complement Cytolysis Inhibiting Agents

Below are MeSH descriptors whose meaning is more general than "Complement Inactivating Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Immunologic Factors [D27.505.696.477]
Immunosuppressive Agents [D27.505.696.477.656]
Complement Inactivating Agents [D27.505.696.477.656.500]

Below are MeSH descriptors whose meaning is related to "Complement Inactivating Agents".

Below are MeSH descriptors whose meaning is more specific than "Complement Inactivating Agents".

Complement Inactivating Agents
Bradykinin B2 Receptor Antagonists

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Complement Inactivating Agents" by people in this website by year, and whether "Complement Inactivating Agents" was a major or minor topic of these publications.

Bar chart showing 25 publications over 12 distinct years, with a maximum of 7 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	0	1	1
2010	1	1	2
2011	1	1	2
2012	2	0	2
2013	1	0	1
2014	1	1	2
2015	1	0	1
2016	2	0	2
2017	1	0	1
2018	2	0	2
2020	1	1	2
2021	5	2	7

Below are the most recent publications written about "Complement Inactivating Agents" by people in Profiles.

Zheng C, Ricci J, Zhang Q, Alawieh A, Yang X, Nadig S, He S, Engel P, Jin J, Atkinson C, Tomlinson S. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.

View in: PubMed
Lei B, Sleiman MM, Cheng Q, Tu Z, Zhu P, Goddard M, Martins PN, Langerude L, Nadig S, Tomlinson S, Atkinson C. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.

View in: PubMed
Toutonji A, Mandava M, Guglietta S, Tomlinson S. Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study. Acta Neuropathol Commun. 2021 07 19; 9(1):126.

View in: PubMed
Zheng C, Sleiman MM, Yang X, He S, Atkinson C, Tomlinson S. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.

View in: PubMed
Annamalai B, Parsons N, Nicholson C, Joseph K, Coughlin B, Yang X, Jones BW, Tomlinson S, Rohrer B. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.

View in: PubMed
Annamalai B, Parsons N, Nicholson C, Obert E, Jones B, Rohrer B. Subretinal Rather Than Intravitreal Adeno-Associated Virus-Mediated Delivery of a Complement Alternative Pathway Inhibitor Is Effective in a Mouse Model of RPE Damage. Invest Ophthalmol Vis Sci. 2021 04 01; 62(4):11.

View in: PubMed
Li C, Patel K, Tu Z, Yang X, Kulik L, Alawieh A, Allen P, Cheng Q, Wallace C, Kilkenny J, Kwon J, Gibney B, Cantu E, Sharma A, Pipkin M, Machuca T, Emtiazjoo A, Goddard M, Holers VM, Nadig S, Christie J, Tomlinson S, Atkinson C. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.

View in: PubMed
Borucki DM, Toutonji A, Couch C, Mallah K, Rohrer B, Tomlinson S. Complement-Mediated Microglial Phagocytosis and Pathological Changes in the Development and Degeneration of the Visual System. Front Immunol. 2020; 11:566892.

View in: PubMed
Annamalai B, Parsons N, Brandon C, Rohrer B. The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization. Mol Vis. 2020; 26:370-377.

View in: PubMed
Tomlinson S, Thurman JM. Tissue-targeted complement therapeutics. Mol Immunol. 2018 10; 102:120-128.

View in: PubMed

People

Explore

Similar Concepts

Top Journals